London, United Kingdom — Hikma Pharmaceuticals PLC (‘Hikma’ or ‘Group’), the multinational pharmaceutical company, today reports its interim results for the six months ended 30 June 2022. During the first half of 2022, core group revenue was flat at $1.213 billion (compared to H1 2021: $1.216 billion) as the strong performance from our Injectables and Branded businesses offset the impact of weaker pricing in Generics. Core operating profit was down 4% to $296 million reflecting lower profit in Generics. Good cashflow from operating activities of $169 million was maintained, in…
